Eupraxia Pharmaceuticals Statistics
Total Valuation
EPRX has a market cap or net worth of $119.43 million. The enterprise value is $116.52 million.
Important Dates
The last earnings date was Thursday, March 20, 2025, after market close.
| Earnings Date | Mar 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
EPRX has 35.85 million shares outstanding. The number of shares has increased by 40.52% in one year.
| Current Share Class | 35.85M |
| Shares Outstanding | 35.85M |
| Shares Change (YoY) | +40.52% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 24.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.75 |
| P/TBV Ratio | 70.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.10, with a Debt / Equity ratio of 0.00.
| Current Ratio | 11.10 |
| Quick Ratio | 10.74 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -28.15 |
Financial Efficiency
Return on equity (ROE) is -157.31% and return on invested capital (ROIC) is -78.04%.
| Return on Equity (ROE) | -157.31% |
| Return on Assets (ROA) | -61.14% |
| Return on Invested Capital (ROIC) | -78.04% |
| Return on Capital Employed (ROCE) | -84.81% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$894,072 |
| Employee Count | 29 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, EPRX has paid $1,804 in taxes.
| Income Tax | 1,804 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.63% in the last 52 weeks. The beta is 1.23, so EPRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.23 |
| 52-Week Price Change | +6.63% |
| 50-Day Moving Average | 3.53 |
| 200-Day Moving Average | 2.98 |
| Relative Strength Index (RSI) | 37.82 |
| Average Volume (20 Days) | 12,677 |
Short Selling Information
The latest short interest is 128,474, so 0.36% of the outstanding shares have been sold short.
| Short Interest | 128,474 |
| Short Previous Month | 44,831 |
| Short % of Shares Out | 0.36% |
| Short % of Float | 0.52% |
| Short Ratio (days to cover) | 20.81 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -27.00M |
| Pretax Income | -23.08M |
| Net Income | -25.93M |
| EBITDA | -26.89M |
| EBIT | -27.00M |
| Earnings Per Share (EPS) | -$0.76 |
Full Income StatementBalance Sheet
The company has $33.10 million in cash and $71,859 in debt, giving a net cash position of $33.03 million or $0.92 per share.
| Cash & Cash Equivalents | 33.10M |
| Total Debt | 71,859 |
| Net Cash | 33.03M |
| Net Cash Per Share | $0.92 |
| Equity (Book Value) | 31.84M |
| Book Value Per Share | 0.05 |
| Working Capital | 31.33M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$29.99 million and capital expenditures -$104,227, giving a free cash flow of -$30.10 million.
| Operating Cash Flow | -29.99M |
| Capital Expenditures | -104,227 |
| Free Cash Flow | -30.10M |
| FCF Per Share | -$0.84 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |